ATE353217T1 - 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren - Google Patents

3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren

Info

Publication number
ATE353217T1
ATE353217T1 AT03757767T AT03757767T ATE353217T1 AT E353217 T1 ATE353217 T1 AT E353217T1 AT 03757767 T AT03757767 T AT 03757767T AT 03757767 T AT03757767 T AT 03757767T AT E353217 T1 ATE353217 T1 AT E353217T1
Authority
AT
Austria
Prior art keywords
inhibitors
phenylphenanthridine
pde
hydroxy
meanings
Prior art date
Application number
AT03757767T
Other languages
English (en)
Inventor
Ulrich Kautz
Beate Schmidt
Dieter Flockerzi
Gerhard Grundler
Ruediger Nave
Rolf-Peter Hummel
Ernst Sturm
Armin Hatzelmann
Johannes Barsig
Degenhard Marx
Hans-Peter Kley
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Application granted granted Critical
Publication of ATE353217T1 publication Critical patent/ATE353217T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/10—Aza-phenanthrenes
    • C07D221/12—Phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
AT03757767T 2002-08-29 2003-08-29 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren ATE353217T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02019336 2002-08-29

Publications (1)

Publication Number Publication Date
ATE353217T1 true ATE353217T1 (de) 2007-02-15

Family

ID=31970272

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03757767T ATE353217T1 (de) 2002-08-29 2003-08-29 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren

Country Status (9)

Country Link
US (2) US7423046B2 (de)
EP (1) EP1536798B1 (de)
JP (1) JP4587295B2 (de)
AT (1) ATE353217T1 (de)
AU (1) AU2003273805B8 (de)
CA (1) CA2496459C (de)
DE (1) DE60311662T2 (de)
ES (1) ES2281658T3 (de)
WO (1) WO2004019945A1 (de)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4587294B2 (ja) * 2002-08-29 2010-11-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−ヒドロキシ−６−フェニルフェナントリジン
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
CA2556086C (en) 2004-02-18 2014-04-01 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
PL2589599T4 (pl) * 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
AR049419A1 (es) * 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
AU2005220034A1 (en) * 2004-03-09 2005-09-15 Nycomed Gmbh Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
EP1725534A1 (de) * 2004-03-10 2006-11-29 Altana Pharma AG Neue amidosubstituierte hydroxy-6-phenylphenanthridine und deren verwendung als pde4-inhibitoren
WO2005085203A1 (en) * 2004-03-10 2005-09-15 Altana Pharma Ag Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
BRPI0615102A2 (pt) * 2005-08-30 2011-05-03 Abbott Lab composto, composições farmacêuticas como inibidores de dipeptidil peptidase-iv (dpp-iv), bem como uso
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
PT2322525E (pt) 2006-04-21 2013-12-26 Novartis Ag Derivados de purina para utilização como agonistas do recetor de adenosina a2a
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
JP2010508315A (ja) 2006-10-30 2010-03-18 ノバルティス アーゲー 抗炎症剤としてのヘテロ環式化合物
RS51644B (sr) 2007-01-10 2011-10-31 Irm Llc. Jedinjenja i preparati kao inhibitori kanal aktivirajuće proteaze
CN101687851B (zh) 2007-05-07 2013-02-27 诺瓦提斯公司 有机化合物
CL2008003651A1 (es) 2007-12-10 2009-06-19 Novartis Ag Compuestos derivados de 3,5-diamino-6-cloropirazinamida sustituida; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una condición inflamatoria o alergica, en particular una enfermedad inflamatoria u obstructiva de las vias respiratorias.
AU2009203693B2 (en) 2008-01-11 2012-06-07 Novartis Ag Pyrimidines as kinase inhibitors
CA2727196A1 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
PL2391366T3 (pl) 2009-01-29 2013-04-30 Novartis Ag Podstawione benzimidazole do leczenia gwiaździaków
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EA201200260A1 (ru) 2009-08-12 2012-09-28 Новартис Аг Гетероциклические гидразоны и их применение для лечения рака и воспаления
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
US20110098311A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorported Compositions for treatment of cystic fibrosis and other chronic diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
EP2673277A1 (de) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
MA34969B1 (fr) 2011-02-25 2014-03-01 Irm Llc Composes et compositions en tant qu inibiteurs de trk
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
CA2848809A1 (en) 2011-09-15 2013-03-21 Novartis Ag 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2882807T3 (es) 2011-09-16 2021-12-02 Novartis Ag Heterociclil carboxamidas N-sustituidas
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
JP6130391B2 (ja) 2011-11-23 2017-05-17 インテリカイン， エルエルシー Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
AU2013243097A1 (en) 2012-04-03 2014-10-09 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
EP2968340A4 (de) 2013-03-15 2016-08-10 Intellikine Llc Kombination von kinaseinhibitoren und verwendungen davon
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
BR112016024484A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase
US9862711B2 (en) 2014-04-24 2018-01-09 Novartis Ag Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
CA2945212A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
CA2954862A1 (en) 2014-07-31 2016-02-04 Novartis Ag Combination therapy
CN108658778A (zh) * 2018-06-19 2018-10-16 上海华堇生物技术有限责任公司 一种3,4-二甲氧基-β-硝基苯乙烯的新制备方法
AU2020290094B2 (en) 2019-06-10 2024-01-18 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis
AU2020338971B2 (en) 2019-08-28 2023-11-23 Novartis Ag Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027055D0 (en) 1990-12-13 1991-02-06 Sandoz Ltd Organic compounds
BR9707233A (pt) * 1996-01-31 1999-07-20 Byk Gulden Lomberg Chem Fab Fenantridinas
SI0889886T1 (en) 1996-03-26 2003-02-28 Altana Pharma Ag Novel phenanthridines substituted in the 6 position
US6127378A (en) * 1996-03-26 2000-10-03 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridines substituted in the 6 position
WO1999005112A1 (en) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituted 6-alkylphenanthridines
JP2001510827A (ja) 1997-07-25 2001-08-07 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 置換６−フェニルフェナントリジン
PT998460E (pt) * 1997-07-25 2004-07-30 Altana Pharma Ag Novos derivados de tetrazole
DK1075477T3 (da) * 1998-05-05 2003-06-30 Altana Pharma Ag Nye benzonaphthyridin-N-oxider
DE60020079T2 (de) 1999-01-15 2006-01-19 Altana Pharma Ag Phenanthridin-N-oxide mit PDE-IV-hemmender Wirkung
TR200501553T2 (tr) * 1999-01-15 2005-06-21 Altana Pharma Ag PDE-IV inhibe edici aktivitesi olan fenilfenantridinler
WO2000042019A1 (en) 1999-01-15 2000-07-20 Byk Gulden Lomberg Chemische Fabrik Gmbh 6-arylphenanthridines with pde-iv inhibiting activity
ES2241571T3 (es) 1999-01-15 2005-11-01 Altana Pharma Ag N-oxidos de fenantrinida con actividad inhividora de pde-iv.
CA2360386A1 (en) 1999-01-15 2000-07-20 Beate Gutterer Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity
WO2001051470A1 (en) * 2000-01-11 2001-07-19 Byk Gulden Lomberg Chemische Fabrik Gmbh Phenanthridine-n-oxides
WO2002006238A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines
WO2002005616A1 (en) * 2000-07-14 2002-01-24 Altana Pharma Ag Novel 6-phenylphenanthridines
ES2236288T3 (es) 2000-07-14 2005-07-16 Altana Pharma Ag 6-heteroarilfenantridinas.
US6936622B2 (en) 2001-02-21 2005-08-30 Altana Pharma Ag 6-phenylbenzonaphthyridines
CA2495597A1 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Novel phenanthridines
JP4587294B2 (ja) * 2002-08-29 2010-11-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐｄｅ４インヒビターとしての２−ヒドロキシ−６−フェニルフェナントリジン
CA2556086C (en) 2004-02-18 2014-04-01 Altana Pharma Ag Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
AR049419A1 (es) 2004-03-03 2006-08-02 Altana Pharma Ag Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo
PL2589599T4 (pl) 2004-03-03 2015-06-30 Takeda Gmbh Nowe hydroksy-6-heteroarylofenantrydyny i ich zastosowanie jako inhibitorów PDE4
AU2005220034A1 (en) * 2004-03-09 2005-09-15 Nycomed Gmbh Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors
WO2005085203A1 (en) 2004-03-10 2005-09-15 Altana Pharma Ag Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
EP1725534A1 (de) 2004-03-10 2006-11-29 Altana Pharma AG Neue amidosubstituierte hydroxy-6-phenylphenanthridine und deren verwendung als pde4-inhibitoren
CA2558390A1 (en) 2004-03-10 2005-09-22 Altana Pharma Ag Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors
PL1856093T3 (pl) 2005-03-02 2010-05-31 Takeda Gmbh Chlorowodorek (2R,4aR,10bR)-6-(2,6-dimetoksy-pirydyn-3-ylo)-9-etoksy-8-metoksy-1,2,3,4,4a,10b-heksahydrofenantrydyn-2-olu

Also Published As

Publication number Publication date
WO2004019945A1 (en) 2004-03-11
DE60311662D1 (en) 2007-03-22
EP1536798A1 (de) 2005-06-08
AU2003273805B2 (en) 2009-10-01
US20090170892A1 (en) 2009-07-02
ES2281658T3 (es) 2007-10-01
JP2006508913A (ja) 2006-03-16
US8202880B2 (en) 2012-06-19
EP1536798B1 (de) 2007-02-07
CA2496459C (en) 2013-06-25
DE60311662T2 (de) 2007-10-25
US20050239818A1 (en) 2005-10-27
AU2003273805B8 (en) 2010-06-17
CA2496459A1 (en) 2004-03-11
US7423046B2 (en) 2008-09-09
JP4587295B2 (ja) 2010-11-24
AU2003273805A1 (en) 2004-03-19

Similar Documents

Publication Publication Date Title
ATE348616T1 (de) 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer
ATE353217T1 (de) 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren
HRP20050228A2 (en) Novel phenanthridines
ATE360627T1 (de) Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
BRPI0608886B8 (pt) derivados de n-sulfonilpirróis e seus usos
EA200601587A1 (ru) Новые амидозамещённые гидрокси-6-фенилфенантридины
NO20071127L (no) Triazoloftalaziner
TW200745028A (en) Novel sulphonylpyrroles
TW200600499A (en) Novel amido-substituted hydroxy-6-phenylphenanthridines
EA200601568A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
DE60316984D1 (de) Benzoylsulfonamide als antitumor-mittel
EA201000566A1 (ru) Гетероциклические сетр ингибиторы
ATE287403T1 (de) 6-phenylbenzonaphthyidine
EA200301101A1 (ru) Производные пиперазина и их применение в качестве ингибиторов pde4
ATE403422T1 (de) Substituierte hydrazone als hemmer von cyclooxygenase-2
NO20064417L (no) Nye isoamidosubstituertehydroksy-6-fenylfenantridiner
ATE508130T1 (de) 3-oxa-10-aza-phenanthrene als pde4- oder pde3/4- inhibitoren
ATE398617T1 (de) Imidazoä4,5-büpyridinderivate als inhibitoren der induzierbaren no-synthase
ATE461189T1 (de) Neue 6-pyridylphenanthridine
ATE364037T1 (de) Tryptasehemmer
DE60200935D1 (de) Diazocinderivate und deren verwendung als tryptase inhibitoren
DE60313331D1 (de) Neue benzonaphthyridine
ATE388710T1 (de) Phthalazinderivate als phosphodiesterase-4-hemmer
ATE417040T1 (de) Nitratester von phenylaminothiophen- essigsäurederivaten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1536798

Country of ref document: EP

EEIH Change in the person of patent owner